Sign in to continue:

Friday, March 20th, 2026

Grove Collaborative Holdings, Inc. Files 8-K with SEC: Company Information, Address, and NYSE Listing Details

Grove Collaborative Holdings, Inc. Regains NYSE Compliance — Potential Impact for Investors

Key Points:

  • Grove Collaborative Holdings, Inc. (NYSE: GROV) receives official notification from the New York Stock Exchange (NYSE) that it has regained compliance with the NYSE’s quantitative continued listing standard.
  • This compliance is specifically related to the minimum market capitalization and stockholders’ equity requirements under Section 802.01B of the NYSE Listed Company Manual.
  • The company’s compliance was achieved as of March 17, 2026.

Detailed Analysis:

On March 17, 2026, Grove Collaborative Holdings, Inc. announced it received a formal notification from the New York Stock Exchange, confirming that it has now regained compliance with the NYSE’s quantitative continued listing standards. These standards are significant: they ensure that only companies meeting specific financial thresholds remain listed and publicly traded on the NYSE, which is a benchmark for investor confidence and market visibility.

The specific requirements Grove Collaborative has met include:

  • Minimum Market Capitalization: The NYSE mandates that listed companies maintain a certain market capitalization, which reflects the total value of the company’s outstanding shares. Falling below the threshold can trigger potential delisting procedures.
  • Stockholders’ Equity Requirement: The company must also meet a minimum level of stockholders’ equity, ensuring the business maintains a solid capital base and financial health.

According to the NYSE’s Section 802.01B, failure to meet these criteria can lead to a company being flagged as non-compliant, which often has severe consequences, including loss of investor confidence, reduced share liquidity, and potential delisting from the exchange.

As of March 17, 2026, Grove Collaborative Holdings, Inc. is back in full compliance with these requirements. This is a crucial development for the company, its shareholders, and potential investors, as it reaffirms the company’s eligibility to remain listed on the NYSE.

What This Means for Shareholders:

  • Restored Confidence: Regaining NYSE compliance immediately removes a major overhang that could have negatively affected the company’s share price and investor sentiment. It signals improved financial health and stability.
  • Liquidity and Institutional Interest: Maintaining the NYSE listing ensures ongoing liquidity for shareholders and keeps the stock accessible to a broader range of institutional investors who may have mandates or restrictions against holding non-compliant or delisted securities.
  • Potential Price Sensitivity: Often, news of regaining compliance can result in a positive share price movement, as it removes uncertainty regarding the company’s future as a listed entity. This is particularly relevant for investors who may have been waiting on the sidelines due to previous compliance issues.

For context, Grove Collaborative Holdings, Inc. trades under the symbol GROV on the NYSE, with its primary registered address at 1301 Sansome Street, San Francisco, CA 94111.

The company’s official signatory for this report is Tom Siragusa, Chief Financial Officer. The report was filed on March 19, 2026.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to do their own research and consult with financial professionals before making investment decisions. The information is derived from Grove Collaborative Holdings, Inc.’s public SEC filings and is believed to be accurate as of the date of publication, but no guarantee of accuracy or completeness is made.

View Grove Collaborative Holdings, Inc. Historical chart here



OrthoPediatrics Corp: Comprehensive Pediatric Orthopedic Implants, Bracing, and Innovation Overview (2025)

OrthoPediatrics Corp. 2025 Annual Report - Investor Analysis...

Hyster-Yale 2025 Financial Results: Tariff Impact, Market Outlook, and Cost Reduction Initiatives for 2026

Hyster-Yale Reports Q4 and Full-Year 2025 Results: Key Inves...

Inhibrx Biosciences, Inc. 2025 Annual Report – Clinical Pipeline, Regulatory Progress, and Company Overview

Inhibrx Biosciences, Inc. 2025 Annual Report – Key Investor ...

   Ad